Welcome to the press section of Arthur D. Little. We put great emphasis on good relations with the media. In the press section, you will find the latest press releases, contact partners and our media echo showing you the most important publications in different countries. We would like to expressly invite the media to contact us if you have additional enquiries or need particular information.
The business model of the pharmaceutical industry is being transformed by digital health. It will significantly extend current business models, or even create completely new ones for the industry. In order to implement innovative solutions ahead of new entrants, pharma companies will need to undergo major transformation programs and convert three completely different value chains: pharma, medical devices for measuring health parameters, and IT solutions to process and connect data. In this article, Ulrica Sehlstedt, Nils Bohlin, Fredrik de Maré and Richard Beetz of Arthur D. Little discuss how pharma companies can get ahead of disruptive innovations and thrive in the digital world. [...]
This article in Digital Health Age explains how the digital revolution is changing the healthcare industry. Patients and consumers are better informed, have wider choice and demand increased personalization. The consumer health space is naturally more oriented towards screening and prevention, and capturing consumers before they become patients. The successful business models of the future will be associated with giving a large population access to awareness and "prevention" solutions. New entrants to the healthcare space and organizations in adjacent industries, as well as existing healthcare players, can take advantage of these opportunities. [...]
Healthcare providers are under pressure to deliver improved medical outcomes while consuming fewer resources. Arthur D. Little’s (ADL) recent global Innovation Excellence study demonstrates that a high performance innovation system generates significant and quantifiable effects on profitability and accelerated time to market for new product development. In its latest viewpoint, ‘The Future of Medtech,’ ADL outlines the future of the medtech industry and its opportunities, as well as how to address future challenges through the implementation of a well-designed Innovation Management System. [...]
After years of low productivity, R&D in leading pharmaceutical and biotech companies is starting to deliver on its promises; the number of New Molecular Entities (NMEs) approved by the US FDA has leveled out and biotech companies’ share prices are rising, indicating profitable business models. Now is the time for launch. Arthur D. Little’s (ADL) latest viewpoint, ‘Launch Excellence for New Medicines,’ assesses the key success factors for the successful launch of new medicines. [...]
Chief Operating Officer
Arthur D. Little Services
+33 1 55 74 29 20